PLEKHA3

Across TCGA pan-cancer cohorts, PLEKHA3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHA3 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLEKHA3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLEKHA3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

UCEC, PDAC, and HNSC are the cancer types where PLEKHA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.902	.006	26	view →
PDAC	OS	Quartile	II,III,IV	0.315	0.696	.009	20	view →
HNSC	DFS	Tertile	III,IV	0.959	0.761	.002	17	view →
LUAD	DFS	Median	III,IV	0.288	0.700	.006	10	view →
CCRCC	OS	Median	II,III,IV	0.571	1.000	.014	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHA3–UCEC (OS)

Open the UCEC breakdown →